JP2024105229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105229A5 JP2024105229A5 JP2024053871A JP2024053871A JP2024105229A5 JP 2024105229 A5 JP2024105229 A5 JP 2024105229A5 JP 2024053871 A JP2024053871 A JP 2024053871A JP 2024053871 A JP2024053871 A JP 2024053871A JP 2024105229 A5 JP2024105229 A5 JP 2024105229A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702762P | 2018-07-24 | 2018-07-24 | |
| US62/702,762 | 2018-07-24 | ||
| JP2021503901A JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| PCT/US2019/043254 WO2020023644A2 (en) | 2018-07-24 | 2019-07-24 | Antibody directed against s. aureus clumping factor a (clfa) |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Division JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105229A JP2024105229A (ja) | 2024-08-06 |
| JP2024105229A5 true JP2024105229A5 (https=) | 2024-10-24 |
Family
ID=67539640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Active JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| JP2024053871A Pending JP2024105229A (ja) | 2018-07-24 | 2024-03-28 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503901A Active JP7525471B2 (ja) | 2018-07-24 | 2019-07-24 | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11155606B2 (https=) |
| EP (1) | EP3840838A2 (https=) |
| JP (2) | JP7525471B2 (https=) |
| CN (2) | CN119176871A (https=) |
| AU (1) | AU2019309366B2 (https=) |
| BR (1) | BR112021001214A2 (https=) |
| CA (1) | CA3107463A1 (https=) |
| MX (1) | MX2021000889A (https=) |
| TW (1) | TWI902669B (https=) |
| WO (1) | WO2020023644A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| DE102018115012A1 (de) | 2018-06-21 | 2019-12-24 | Carl Zeiss Microscopy Gmbh | Teilchenstrahlsystem |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| TWI743626B (zh) | 2019-01-24 | 2021-10-21 | 德商卡爾蔡司多重掃描電子顯微鏡有限公司 | 包含多束粒子顯微鏡的系統、對3d樣本逐層成像之方法及電腦程式產品 |
| DE102019008249B3 (de) | 2019-11-27 | 2020-11-19 | Carl Zeiss Multisem Gmbh | Teilchenstrahl-System mit einer Multistrahl-Ablenkeinrichtung und einem Strahlfänger, Verfahren zum Betreiben des Teilchenstrahl-Systems und zugehöriges Computerprogrammprodukt |
| WO2024231440A1 (en) * | 2023-05-09 | 2024-11-14 | Astrazeneca Ab | Bispecific anti-pseudomonas antibodies with modified fc regions and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1377314E (pt) | 2001-01-26 | 2012-01-02 | Inhibitex Inc | Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
| CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
| US20050226878A1 (en) | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| US20080131457A1 (en) | 2006-06-12 | 2008-06-05 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| JP2011526792A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| MX2011012248A (es) | 2009-05-18 | 2012-02-29 | Univ Wuerzburg J Maximilians | Anticuerpos o sus fragmentos dirigidos contra un epitope de staphylococcus aureus de isaa o isab. |
| EP4015523A1 (en) | 2010-05-05 | 2022-06-22 | New York University | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof |
| PT2673373T (pt) | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| NZ764564A (en) | 2011-06-19 | 2022-10-28 | Univ New York | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| DK2833899T3 (da) | 2012-03-19 | 2020-09-28 | Tecnifar Ind Tecnica Farmaceutica S A | Sammensætninger, der omfatter cocktails af antibakterielle fager, og anvendelser deraf til behandling af bakterieinfektioner |
| KR20210083389A (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| BR112015010125A2 (pt) | 2012-11-06 | 2017-08-22 | Medimmune Llc | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente |
| RU2016119052A3 (en) | 2013-10-17 | 2018-09-10 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody sequences |
| CA2932819A1 (en) | 2013-12-09 | 2015-06-18 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| MX2016007212A (es) | 2013-12-19 | 2016-09-07 | Arsanis Biosciences Gmbh | Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos. |
| ES2869459T3 (es) | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| CN107873034A (zh) | 2015-04-17 | 2018-04-03 | 阿尔萨尼斯生物科学有限责任公司 | 抗金黄色葡萄球菌抗体组合制剂 |
| WO2017075188A2 (en) * | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
| JP7525471B2 (ja) | 2018-07-24 | 2024-07-30 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体 |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| TWI895248B (zh) | 2018-10-09 | 2025-09-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
-
2019
- 2019-07-24 JP JP2021503901A patent/JP7525471B2/ja active Active
- 2019-07-24 CN CN202411220211.6A patent/CN119176871A/zh active Pending
- 2019-07-24 WO PCT/US2019/043254 patent/WO2020023644A2/en not_active Ceased
- 2019-07-24 BR BR112021001214-1A patent/BR112021001214A2/pt unknown
- 2019-07-24 EP EP19749544.3A patent/EP3840838A2/en active Pending
- 2019-07-24 US US16/521,223 patent/US11155606B2/en active Active
- 2019-07-24 CA CA3107463A patent/CA3107463A1/en active Pending
- 2019-07-24 MX MX2021000889A patent/MX2021000889A/es unknown
- 2019-07-24 AU AU2019309366A patent/AU2019309366B2/en active Active
- 2019-07-24 TW TW108126187A patent/TWI902669B/zh active
- 2019-07-24 CN CN201980058857.XA patent/CN112672788B/zh active Active
-
2021
- 2021-09-23 US US17/483,162 patent/US11970527B2/en active Active
-
2024
- 2024-03-28 JP JP2024053871A patent/JP2024105229A/ja active Pending
- 2024-03-29 US US18/621,921 patent/US20240352098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105229A5 (https=) | ||
| JP2023075294A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| EP2890711B1 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
| JP2021534762A5 (https=) | ||
| JP2021526022A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| TW202126693A (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| CN106749667B (zh) | 一种抗癌胚抗原的纳米抗体及其应用 | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP7851923B2 (ja) | インターロイキン１アルファに特異的な真のヒト抗体 | |
| JP7830445B2 (ja) | インターロイキン１アルファに特異的な真のヒト抗体 | |
| CN118702814B (zh) | 一种抗ngf单克隆抗体及其应用 | |
| TW201127401A (en) | Compositions and methods for treating inflammatory disorders | |
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2023520969A5 (https=) | ||
| CN119306838B (zh) | 一种抗人pd-1的鲨鱼纳米抗体及其应用 | |
| CN118165106A (zh) | 抗犬il-31单克隆抗体及其应用 | |
| JP2023506834A5 (https=) | ||
| JP2019510474A (ja) | トロンビン抗体、その抗原結合フラグメント及び医薬用途 | |
| JP2023553938A5 (https=) | ||
| CN110114370B (zh) | 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段 | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| Yuan et al. | Construction of human nonimmune library and selection of scFvs against IL-33 | |
| JP2024503425A5 (https=) |